Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06118385Phase 1Completed

Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.

Role: lead

NCT03194217Phase 2Completed

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

Role: lead

NCT04737304Phase 1Completed

A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

Role: lead

All 3 trials loaded